Related Experiment Video
Updated: Apr 17, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
35.1K
PGWD: integrating personal genome for warfarin dosing.
Yidan Pan1, Ronghai Cheng, Zhoufang Li
1Department of Biology, South University of Science and Technology of China, Shenzhen, China.
Interdisciplinary Sciences, Computational Life Sciences
|February 10, 2015
Summary
Personal genome sequencing data can now inform warfarin dosing. PGWD is a new web tool that analyzes this high-throughput genetic data for accurate warfarin dosage prediction.
Area of Science:
- Pharmacogenomics
- Bioinformatics
- Genetics
Background:
- Warfarin is crucial for preventing thrombosis and blood clots.
- Warfarin dosage is significantly influenced by genetic variations in CYP2C9 and VKORC1 genes.
- Current genetic variant detection methods (e.g., real-time PCR) are low-throughput.
Purpose of the Study:
- To develop a bioinformatics tool for accurate warfarin dosing using high-throughput genome sequencing data.
- To address the gap in existing software that relies on low-throughput genetic information.
Main Methods:
- Development of PGWD, a web-based bioinformatics tool.
- Analysis of personal whole genome sequencing data.
- Integration of genetic data with clinical information for warfarin dosing.
Main Results:
- PGWD analyzes high-throughput genome sequencing data for warfarin dosing.
- The tool integrates genetic insights with clinical data for personalized recommendations.
- PGWD provides a solution for accurate warfarin dosage prediction from comprehensive genomic data.
Conclusions:
- PGWD enables precise warfarin dosing by leveraging personal genome sequencing data.
- The tool enhances pharmacogenomic applications by utilizing high-throughput genetic information.
- PGWD represents a significant advancement in personalized medicine for warfarin therapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:29Pharmacogenetics and Pharmacogenomics: Overview
202
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
202
01:29Pharmacogenomics: Identification of New Drug Targets
98
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
257
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
257